Patent · US Active

Aminopyrimidinones as interleukin receptor-associated kinase inhibitors

US9221809B2 · kind B2 · utility

4Cited by

5References

3Claims

0Family size

Assignee

Merck Sharp & Dohme LLC · US

Inventors

W. Michael Seganish · Scotch Plains, US
Stephanie Nicole Brumfield · Cranbury, US
Jongwon Lim · Lexington, US
Julius J. Matasi · Monmouth Junction, US
William T. McElroy · Plainfield, US
Deen Tulshian · Lebanon, US
Brian J. Lavey · New Providence, US
Michael D. Altman · Cambridge, US
Craig R. Gibeau · Holliston, US
John W. Lampe · Orange, US
Joey L. Methot · Westwood, US
Liang Zhu · Waltham, US

Key dates

Filing date	Oct 26, 2012
Grant date	Dec 29, 2015
Priority date	—
Expiry date	Oct 26, 2032

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D513/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This invention relates to aminopyrimidinone compounds of Formula (I) that are inhibitors of Interleukin receptor-associated kinases, in particular IRAK-4, and are useful in the treatment or prevention of inflammatory diseases, including rheumatoid arthritis and inflammatory bowel disease.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.